Risk Factors.
−Removed: You should carefully consider the information set forth in this Quarterly Report on Form 10-Q and the risk factors discussed below and in the sections entitled “Summary of Risk Factors” and “Risk Factors” in our Annual Report, which could materially affect our business, financial condition, results of operations, or prospects.
+Added: Information set forth in this Quarterly Report on Form 10-Q and the risk factors discussed below and in the sections entitled “Summary of Risk Factors” and Part I, “Item 1A.
+Added: Risk Factors” in the Annual Report, includes risks which could materially affect our business, financial condition, results of operations, or prospects.
These risks, as well as other risks and uncertainties, could materially and adversely affect our business, results of operations and financial condition, which in turn could materially and adversely affect the trading price of shares of our common stock.
21 unchanged sentences
As a result, Broad entered the priority phase of the interference as “Senior Party” while CVC remained the “Junior Party” for purposes of determining which entity was the first to invent the inventions at issue.
−Removed: We cannot predict with any certainty how long it will take before the PTAB issues a decision at the conclusion of the priority phase.
+Added: On February 28, 2022, the PTAB issued a decision regarding the priority phase of the interference determining that Broad was the first entity to invent the claims at issue.
+Added: This decision has been appealed by the University of California, the University of Vienna, and Emmanuelle Charpentier and the Broad has cross-appealed.
+Added: It is uncertain when or in what manner the U.S.
+Added: Court of Appeals for the Federal Circuit will act on these appeals.
On December 14, 2020, the PTAB, declared two new interferences involving a pending U.S.
32 unchanged sentences
If we are unable to obtain an exclusive license to any such third party co-owners’ interest in such patents, patent applications or other intellectual property rights, such co-owners may be able to license their rights to other third parties, including our competitors.
−Removed: In addition, we may need the cooperation of any such co-owners to enforce any patents, including any patents that issue from patent applications, against third parties, and such cooperation may not be provided to us.
+Added: In addition, we may need the cooperation of any such co-owners to enforce any patents, including any patents that issue from patent applications, against third parties, and such cooperation
+Added: may not be provided to us.
Any of the foregoing could have a material adverse effect on the conduct of our business, financial condition, results of operations, and prospects.
19 unchanged sentences
Description of Exhibit
−Removed: Employment Offer Letter, dated Se ptember 22 , 2021, between the Registrant and B ruce Eaton
−Removed: License Agreement, dated August 29, 2014, between the Registrant and The General Hospital Corporation, d/b/a Massachusetts General Hospital
−Removed: Second Amendment to the Exclusive Patent License Agreement, by and between the Company and The General Hospital Corporation, d/b/a Massachusetts General Hospital, dated November 17, 2016
−Removed: License Agreement, dated October 10, 2014, between the Registrant and Duke University
−Removed: Letter Agreement, dated October 9, 2015, between the Registrant and Duke University
−Removed: License Agreement, dated October 29, 2014, among the Registrant, the President and Fellows of Harvard College, and the Broad Institute, Inc.
−Removed: License and Collaboration Agreement, dated May 26, 2015, between the Registrant and Juno Therapeutics, Inc.
Rule 13a-14(a) Certification of Principal Executive Officer
1 unchanged sentence
Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C.
−Removed: The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, formatted in Inline XBRL (eXtensible Business Reporting Language):
+Added: The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, formatted in Inline XBRL (eXtensible Business Reporting Language):
(i) Consolidated Balance Sheets (unaudited), (ii) Consolidated Statements of Operations (unaudited), (iii) Consolidated Statements of Comprehensive Loss (unaudited), (iv) Consolidated Statements of Stockholders’ Equity (unaudited), (v) Consolidated Statements of Cash Flows (unaudited) and (vi) Notes to Condensed Consolidated Financial Statements (unaudited), tagged as blocks of text and including detailed tags.
−Removed: The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, formatted in Inline XBRL.
+Added: The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, formatted in Inline XBRL.
* Filed herewith
−Removed: † Filed with this Quarterly Report on Form 10-Q solely for the purpose of transitioning these previously-filed exhibits, which are the subject of expiring confidential treatment orders, to the rules governing the filing of redacted exhibits under Regulation S-K Item 601(b)(10)(iv) pursuant to the SEC’s CF Disclosure Guidance:
−Removed: Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
+ The certifications furnished in Exhibit 32.1 that accompany this Quarterly Report on Form 10-Q are not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
2 unchanged sentences
EDITAS MEDICINE, INC.
−Removed: November 9, 2021
/s/ Michelle Robertson
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.